Wednesday, 18 November 2026European Markets

ERYTECH PHARMA Stock Over 30% Up In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 30.73% in 21 sessions from €0.59 to €0.77 at 19:54 est on friday, after three consecutive sessions in a row of losses. cac 40 is sliding 1.78% to €7,187.27, following the last session's upward trend.

erytech pharma's last close was €0.82, 63.52% below its 52-week high of €2.26.

about erytech pharma

erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.

earnings per share

as for profitability, erytech pharma has a trailing twelve months eps of €-0.93.

more news about erytech pharma (eryp.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 24 Feb 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›